Companies in #Duchenne Muscular Dystrophy

CureDuchenne is a nonprofit focused on accelerating Duchenne muscular dystrophy research and care. Founded in 2003, it has funded multiple DMD gene therapy and exon-skipping programs and is a major patient-advocacy partner in the DMD therapeutics space.

Dyne Therapeutics (NASDAQ: DYN) is a clinical-stage muscle disease company developing targeted therapeutics for genetically driven muscle disorders including Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and facioscapulohumeral muscular dystrophy (FSHD). Its FORCE platform delivers oligonucleotides to muscle tissue.

Satellos Bioscience is a clinical-stage biotechnology company developing novel small-molecule therapies to treat degenerative muscle diseases, with lead candidate SAT-3247 in Phase 2 development for Duchenne muscular dystrophy. The company reported six-month interim data from the TRAILHEAD study in July 2026 showing reduced muscle-fat fraction and improved biomarker signals, and received FDA Fast Track designation for SAT-3247 in June 2026. Satellos is dual-listed on Nasdaq and the TSX and reported cash and equivalents of approximately Cdn $97.5 million as of Q1 2026 with cash runway through 2027.